Absci (ABSI) Q3 2025 earnings summary

Executive summary

• Interim Phase I results for ABS-101 showed extended half-life and favorable safety, but did not surpass next-gen competitors; company seeking partnership for further development.

• ABS-201 development accelerated for androgenetic alopecia (AGA) with Phase I/IIa trial to start December 2025 and interim proof of concept readout in H2 2026; expanded into endometriosis with Phase II trial initiation planned for Q4 2026 and interim data in H2 2027.

• Strategic focus and capital reallocated to ABS-201 in AGA and endometriosis; ABS-101 to be partnered out after Phase I.

• AI-driven pipeline includes ABS-301 (immuno-oncology) and ABS-501 (anti-HER2), both in preclinical stages and seeking partners.

• Strategic collaborations and co-development partnerships continue to diversify the portfolio and balance risk and return.

Financial highlights

• Q3 2025 revenue was $0.4 million, down 78% year-over-year, reflecting ongoing partnered programs.

• R&D expenses were $19.2 million, up from $18.0 million year-over-year, driven by internal program advancement.

• SG&A expenses decreased to $8.4 million from $9.3 million year-over-year due to lower personnel costs.

• Net loss for Q3 2025 was $28.7 million, compared to $27.4 million in Q3 2024.

• Cash, equivalents, and marketable securities totaled $152.5 million as of September 30, 2025, up from $117.5 million at June 30, 2025.

Outlook and guidance

• ABS-201 Phase I/IIa in AGA to begin dosing in December 2025; interim efficacy data expected H2 2026.

• ABS-201 Phase II in endometriosis to initiate Q4 2026, with interim readout in H2 2027.

• Cash runway expected to fund operations into H1 2028, with potential upside from new partnerships or asset transactions.

• At least one large pharma partnership anticipated by year-end 2025.

• Continued investment in AI platform, early-stage pipeline, and talent.